MBX-1416 by MBX Biosciences Inc for Hypoglycemia: Likelihood of Approval

MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.

Optimind Pharma Closes Second Tranche of Private Placement | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – July 29, 2024) – Optimind Pharma Corp. (CSE: OMND) (“Optimind” or the “Company”) announces it has closed the second trance of its

July 29, 2024

SGLT2 Inhibitor No Help for ICU Patients With Acute Organ Dysfunction

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving

June 15, 2024

FDA reprimands Bristol Myers over misleading efficacy claims on Krazati website

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.